Recon: Global license deal to provide COVID antibody test tech free to poorer countries; GSK partners with Arrowhead for NASH drug

• Elizabeth Holmes’ defense lets Theranos founder play role of young do-gooder in second day on stand (CNBC) (Law360)
• Holmes to take stand for third day in Theranos fraud trial (Reuters)
• Why You Can’t Find Cheap At-Home Covid Tests (KHN)
• GSK dives into NASH, RNA interference with Arrowhead deal (BioPharmaDive)
• Califf’s profitable industry ties spark fresh criticism (Politico)
• Biogen Alzheimer’s Drug Shows Brain Swelling in 35% of Patients (Bloomberg) (Fierce) (JAMA)

• EMA receives application for marketing authorisation for Lagevrio (molnupiravir) for treating patients with COVID 19 (EMA)
• AstraZeneca calls on UK to increase science investment (FT)
• Eight years and $1.3B later, AstraZeneca finally unveils Cambridge R&D palace (Endpoints) (Reuters)
• At busy Visp site, Lonza will up microbial services by 50% (Endpoints)
• Global license deal to provide COVID antibody test tech free to poorer countries – WHO (Reuters) (AP) (WHO)
• WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19 (WHO)
• Success with use of real world data in medicines research: Joining the dots of the European ecosystem (EHDEN)

• U.S. govt asks court to immediately lift stay on COVID vaccine rule (Reuters)
• White House says U.S. will not lock down to fight Covid as European nations implement restrictions (CNBC)
• Senate Democrats call on Biden to push for COVID-19 vaccine patent waivers at WTO (The Hill)
• Israel starts vaccinating young children as coronavirus cases rise (Reuters)

• FDA approves pricey new treatment for ultra-rare and aggressive form of sarcoma (Endpoints) (FDA) (Fierce)
• Vaccibody gets a new name and loads up with nearly $1B in biobucks for new vaccine pact with Regeneron (Endpoints)
• $107B in 2+ years? Pfizer’s Covid-19 vaccine may redefine ‘megablockbuster’ by 2022 — analyst (Endpoints)
• Califf Outlines Clinical Trial Reform Message, Which Could Travel With Him To Commissioner’s Office (Pink Sheet)
• Sagent Pharmaceuticals recalls injectable seizure med thanks to familiar packaging glitch (Fierce)
• Clozapine REMS Program Paused After Problems With Re-Certification (Pink Sheet)
• Growing Complex Generic Application Load May Force US FDA Staffing Changes (Pink Sheet)
• Dragonfly gets Merck on second TriNKET candidate since 2018 collab; Chinese eye gene therapy developer nabs $60M (Endpoints)
• A fledgling transpacific biotech grabs a launch round to dive into oncology and autoimmune research (Endpoints)

• Power Morcellation Containment Devices Placed In FDA Class II (MedtechInsight)

• Ranbaxy Can't Shake MDL Antitrust Claims As Trial Nears (Law360)
• PTAB Axes OxyContin Patent After Purdue Ch. 11 Delay (Law360)
• Teva Says Mylan Is Just Unhappy About MS Drug Competition (Law360)
• DOJ-Walmart Opioid Battle Halted As High Court Reviews CSA (Law360)
• Sanofi Unit To Pay $180M In Disease Treatment Patent Fight (Law360)